Apogee Therapeutics에 대한 매도 수량은 투자자에게 Apogee Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Apogee Therapeutics (NASDAQ:APGE) 주식, 공매도 수량 보고

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Apogee Therapeutics Inc

PGHL

Primega Group Holdings Receives Nasdaq Notification Regarding Non-Compliance with Minimum Bid Price Requirement

Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares traded higher premarket on Friday after it disclosed that six new <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44315576/palantir-warp-speed-accelerates-announces-six-new-customers-that-are-re-industrializing-american-m" rel="noreferrer noopener">customers are adopting Warp Speed</a>.
The company said in a statement Thursday that Epirus, Red Cat, Saildrone, Saronic, Ursa Major, and SNC are the latest companies to leverage Warp Speed.
Since launch, Palantir Warp Speed has introduced key advancements, including MRP Speed for continuous network planning that optimizes material resource planning to prevent shortages and quickly address disruptions.
The platform enables rapid ERP data access, unlocking information from 10+ systems in under 24 hours, eliminating costly and time-consuming integrations.
It also enhances AI command and control at the edge, allowing AI-enabled fleets to operate seamlessly across various connectivity, hardware, and compliance environments.
Red Cat is leveraging Warp Speed to accelerate the production and delivery of assets, supporting critical missions for the Department of Defense.
Saildrone leverages Warp Speed for real-time production planning, optimizing fleet management, procurement, and demand forecasting.
Saronic utilizes Warp Speed to scale operations, with an initial focus on material resource planning and engineering change management.
Ursa Major leverages Warp Speed to enhance digital production agility, rapidly scaling solid and liquid rocket motor production while maintaining safety and innovation speed.
Emily Nguyen, Palantir&#8217;s Head of Industrials, said, &#8220;We designed Warp Speed to enable faster, safer, and more efficient production of formidable machinery that is critical to America&#8217;s leadership — from sea vessels, to drones, to propulsion systems.&#8221;
Yesterday, the company disclosed a strategic deal with Databricks to merge AI operating system with Databricks' platform for AI,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/contracts/25/03/44304895/palantirs-new-strategic-deal-with-databricks-accelerates-adoption-of-autonomous-genai-workflows" rel="noreferrer noopener">data warehousing, and data engineering</a>.
Investors can gain exposure to the stock via&nbsp;Roundhill ETF Trust Roundhill PLTR WeeklyPay ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/PLTW#BATS">PLTW</a>) and&nbsp;Direxion Daily PLTR Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTU#NASDAQ">PLTU</a>).
Price Action: PLTR shares are up 2.55% at $81.65 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44305045/archer-taps-palantirs-ai-to-supercharge-electric-aircraft-production-and-flight-tech" target="_blank" rel="noreferrer noopener">Archer Taps Palantir&#8217;s AI to Supercharge Electric Aircraft Production and Flight Tech</a></li>
</ul>
Image via Shutterstock.

Large Cap

Contracts

PLTR

PLTU

Roundhill ETF Trust Roundhill PLTR WeeklyPay ETF

PLTW

Palantir's Warp Speed Gains Momentum: Six New Customers Onboard

AIRS

Airsculpt Technologies Expect The Reduction In Marketing Activity At The End Of 2024 To Pressure Q1 Performance

Raymond James analyst Ric Prentiss upgrades Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) from Outperform to Strong Buy and lowers the price target from $128 to $122.

Upgrades

Price Target

Analyst Ratings

Raymond James Upgrades Crown Castle to Strong Buy, Lowers Price Target to $122

For the first quarter of 2025, Tuniu expects to generate RMB116.6 million to RMB122.0 million of net revenues, which represents an 8% to 13% increase year-over-year compared with net revenues in the corresponding period in 2024. This forecast reflects Tuniu's current and preliminary view on the industry and its operations, which is subject to change.

Guidance

TOUR

Tuniu Expects Q1 Revenue Of RMB116.6M-RMB122.0M, Up By 8%-13% YoY

AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.04) by 100 percent. This is a 900 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $39.178 million which missed the analyst consensus estimate of $43.386 million by 9.70 percent. This is a 17.71 percent decrease over sales of $47.608 million the same period last year.

Earnings

Earnings Misses

AirSculpt Technologies Q4 2024 Adj. EPS $(0.08) Misses $(0.04) Estimate, Sales $39.178M Miss $43.386M Estimate

Tuniu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOUR#NASDAQ">TOUR</a>) reported quarterly losses of $(0.03) per share. This is a 400 percent decrease over earnings of $0.01 per share from the same period last year. The company reported $14.07 million in sales this quarter. This is a 0.02 percent decrease over sales of $14.08 million the same period last year.

Tuniu Q4 2024 EPADS $(0.03) Down From $0.01 YoY, Sales $14.07M Down From $14.08M YoY

On March 14, 2025, the Board resolved to form a special committee consisting of its three independent directors.

CANG

Cango Recently Receives Preliminary Non-binding Letter Of Intent From Enduring Wealth Capital Limited

Raymond James analyst Srini Pajjuri initiates coverage on Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Outperform rating and announces Price Target of $82.

Initiation

ALAB

Raymond James Initiates Coverage On Astera Labs with Outperform Rating, Announces Price Target of $82

<a href="https://www.reuters.com/business/autos-transportation/tesla-plans-model-y-costing-least-20-less-produce-defend-china-share-sources-say-2025-03-14/" title="https://www.reuters.com/business/autos-transportation/tesla-plans-model-y-costing-least-20-less-produce-defend-china-share-sources-say-2025-03-14/">https://www.reuters.com/business/autos-transportation/tesla-plans-model-y-costing-least-20-less-produce-defend-china-share-sources-say-2025-03-14/</a>

TSLA

Reuters Reported Earlier, Tesla Plans 20% Lower-Cost Model Y Built In Shanghai From 2026; Versions Also Planned For Europe, North America

<a href="https://www.reuters.com/business/energy/china-state-firms-curb-russian-oil-imports-sanctions-risks-sources-say-2025-03-14/" title="https://www.reuters.com/business/energy/china-state-firms-curb-russian-oil-imports-sanctions-risks-sources-say-2025-03-14/">https://www.reuters.com/business/energy/china-state-firms-curb-russian-oil-imports-sanctions-risks-sources-say-2025-03-14/</a>

Commodities

Markets

Reuters Reported Earlier, China State Firms Curb Russian Oil Imports On Sanctions Risks

RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) reported quarterly earnings of $0.03 per share. This is a 43.48 percent decrease over earnings of $0.05 per share from the same period last year. The company reported $111.45 million in sales this quarter. This is a 52.03 percent increase over sales of $73.31 million the same period last year.

RLX Technology Q4 Adj $0.03 Down From $0.05 YoY, Sales $111.45M Up From $73.31M YoY

Macro Economic Events

Econ #s

Economics

China New Loans For February 1,010.0B Vs. 2,150.0B Est.; 5,130.0B Prior

B of A Securities analyst Michael McGovern maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and lowers the price target from $270 to $220.

CVNA

B of A Securities Maintains Buy on Carvana, Lowers Price Target to $220

As a part of the strategy, the company's board of directors has approved the declaration of a special cash dividend of $6.30 per share. The total amount of the special dividend payment will be approximately $1.5 billion, based on the current number of shares outstanding. The special cash dividend is payable on April 17, 2025, to stockholders of record on April 3, 2025.

Dividends

Pilgrim's Pride Announces $6.30/Share Special Dividend Payable April 17, Plans Investments In Brand Growth, Prepared Foods, And Retail Expansion

WIIM

RDUS

Radius Recycling shares are trading higher after the company disclosed a merger deal with Toyota Tsusho America, Inc. for $30.00 per share in cash

Baird analyst David George upgrades American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) from Underperform to Neutral and maintains the price target from $265 to $265.

Baird Upgrades American Express to Neutral, Maintains Price Target to $265

Radius Recycling, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDUS#NASDAQ">RDUS</a>) shares are shooting higher premarket on Friday. On Thursday, the company disclosed a definitive merger agreement with Toyota Tsusho America, Inc. <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44317642/radius-recycling-to-be-acquired-by-u-s-subsidiary-of-toyota-tsusho-corporation-ttc-accelerating-in" rel="noreferrer noopener">for $30.00 per share in cash</a>.
The acquisition price offers around a 115% premium over Radius&#8217; closing share price, and around a 102% premium over the 90-day volume-weighted average share price (VWAP) on March 12, 2025.
The total implied enterprise value of the transaction, including net debt, is approximately $1.34 billion.
The transaction is expected to close in the second half of 2025, pending approval by Radius&#8217; shareholders and other customary closing conditions.
Toyota Tsusho, which is the U.S. subsidiary of Toyota Tsusho Corporation&nbsp;(TTC) expects Radius to become a consolidated subsidiary during <a target="_blank" href="https://www.toyota-tsusho.com/english/press/upload_files/4cb197adb99df7a36ed659cd47a65b11.pdf" rel="noreferrer noopener">the </a>next fiscal year (fiscal year ending March 31, 2026).
Radius anticipates leveraging TTC&#8217;s strong connections with automotive OEMs and suppliers at all tiers, which will open up more opportunities to collaborate with metals consumers.
This expanded customer base will strengthen Radius&#8217; operational platform, enabling it to invest in facilities, drive growth, and offer enhanced products and services.
Tamara L. Lundgren, Radius&#8217; Chairman and Chief Executive Officer, said, &#8220;We are excited to have reached this agreement with TTC, which builds on our longstanding relationship and provides us with increased opportunities for our talented team, broader products and services for our suppliers, customers and communities, and an expanded platform for our more than 100 operating sites while delivering significant immediate value to our shareholders,&#8221;&nbsp;
As of December 31, 2024, TTC&#8217;s cash and cash equivalent stood <a target="_blank" href="https://www.toyota-tsusho.com/english/ir/earnings-presentations/upload_files/E_tanshin_104_3Q.pdf" rel="noreferrer noopener">at </a>JPY860 billion (around $5.78 billion).
In January, Radius reported first-quarter&nbsp;revenue of&nbsp;$656.54 million, missing&nbsp;the consensus of&nbsp;$665.6 million, and adjusted loss per share of $1.33,&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42876979/radius-recyclings-q1-fy25-revenue-falls-short-declines-in-ferrous-sales-weigh-on-results" rel="noreferrer noopener">missing the consensus loss of $0.10</a>.
Price Action: RDUS shares are up 109.0% at $28.55 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44312560/goldman-sachs-sees-favorable-supply-demand-outlook-for-mosaic-bullish-on-fmc-and-corteva" target="_blank" rel="noreferrer noopener">Goldman Sachs Agri Stock Picks: Corteva&#8217;s R&amp;D Edge, FMC&#8217;s Pipeline, And Mosaic&#8217;s Phosphate Advantage Set Up Strong Growth</a></li>
</ul>
Photo via Shutterstock

Small Cap

Trading Ideas

Radius Recycling Lands Merger Deal At 115% Premium, Stock Skyrockets

DOYU

DouYu Intl Hldgs Q4 Adj EPADS $(0.31), Sales $155.63M Down From $182.53M YoY

WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) reported quarterly losses of $(3.51) per share. The company reported quarterly sales of $49.50 million which beat the analyst consensus estimate of $48.53 million by 2.00 percent.

Earnings Beats

WeRide FY 2024 GAAP EPADS $(3.51), Sales $49.50M Beat $48.53M Estimate

Health Care

Press Releases

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Comments

Apogee Therapeutics

매도 수량

Apogee Therapeutics (NASDAQ:APGE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌